Provenge is a patient specific therapeutic cancer vaccine for prostate cancer (CaP).
Dendreon, which expects to receive a European approval for the product’s marketing authorisation application (MAA) by 2013, meanwhile wants to outsource to a contract manufacturing organisation (CMO), reported In-pharmatechnologist.com.
The German facility is expected to help the first phase of the European expansion, with other facilities possibly being constructed in the near future.
Once the construction of production facility is completed and approved Dendreon is confident of meeting commercial supply requirements using its Germany facility.